Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
US Patent 10821375 Continuous production of particles
Overview
Structured Data
Issues
Contributors
Activity
All edits
Edits on 7 Aug, 2024
"update inverses"
Golden AI
edited on 7 Aug, 2024
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent Citations Received
0
Edits on 26 Jun, 2024
"update inverses"
Golden AI
edited on 26 Jun, 2024
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent Citations Received
US Patent 12016861 Amorphous nilotinib microparticles and uses thereof
0
Edits on 5 Jun, 2024
"update inverses"
Golden AI
edited on 5 Jun, 2024
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent Citations Received
US Patent 11998548 Amorphous nilotinib microparticles and uses thereof
0
Edits on 15 May, 2024
"update inverses"
Golden AI
edited on 15 May, 2024
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent Citations Received
US Patent 11980619 Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
0
Edits on 13 Sep, 2023
"update inverses"
Golden AI
edited on 13 Sep, 2023
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent Citations Received
US Patent 11752105 Spray drying process with continuous preparation of spray solution
Edits on 25 May, 2023
"Remove website redirecting to Patent Public Search front page"
Golden AI
edited on 25 May, 2023
Edits made to:
Infobox
(
-1
properties)
Infobox
Official Website
https://pdfpiw.uspto.gov/.piw?Docid=10821375
0
0
Edits on 30 Apr, 2023
"update inverses"
Golden AI
edited on 30 Apr, 2023
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent Citations Received
US Patent 11633398 Amorphous solid dispersions of dasatinib and uses thereof
0
Edits on 28 Apr, 2023
"update citations for inverse infoboxes"
Golden AI
edited on 28 Apr, 2023
Infobox
Patent Citations Received
US Patent 11413290 Amorphous solid dispersions of dasatinib and uses thereof
0
Edits on 3 Apr, 2023
"update citations for inverse infoboxes"
Golden AI
edited on 3 Apr, 2023
Infobox
Patent Citations Received
US Patent 11298356 Amorphous solid dispersions of dasatinib and uses thereof
0
Edits on 1 Apr, 2023
"Entity importer update"
Golden AI
edited on 1 Apr, 2023
Infobox
Is a
Patent
0
Patent Jurisdiction
United States Patent and Trademark Office
0
Patent Number
10821375
0
Date of Patent
November 3, 2020
0
Patent Application Number
15562823
0
Date Filed
March 30, 2016
0
Official Website
https://pdfpiw.uspto.gov/.piw?Docid=10821375
0
Patent Citations Received
US Patent 11298356 Amorphous solid dispersions of dasatinib and uses thereof
0
US Patent 11324745 Amorphous solid dispersions of dasatinib and uses thereof
0
US Patent 11389450 Amorphous nilotinib microparticles and uses thereof
0
US Patent 11413290 Amorphous solid dispersions of dasatinib and uses thereof
0
US Patent 11559485 Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
0
Patent Primary Examiner
Andrew S Rosenthal
0
Edits on 28 Mar, 2023
"update citations for inverse infoboxes"
Golden AI
edited on 28 Mar, 2023
Infobox
Patent Citations Received
US Patent 11559485 Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
0
Edits on 24 Mar, 2023
"update citations for inverse infoboxes"
Golden AI
edited on 24 Mar, 2023
Infobox
Patent Citations Received
US Patent 11389450 Amorphous nilotinib microparticles and uses thereof
0
Edits on 25 Jan, 2023
"update inverses"
Golden AI
edited on 25 Jan, 2023
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent Citations Received
US Patent 11559485 Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
0
Edits on 26 Sep, 2022
"update citations for inverse infoboxes"
Golden AI
edited on 26 Sep, 2022
Infobox
Patent Citations Received
US Patent 11389450 Amorphous nilotinib microparticles and uses thereof
0
"update citations for inverse infoboxes"
Golden AI
edited on 26 Sep, 2022
Infobox
Patent Citations Received
US Patent 11298356 Amorphous solid dispersions of dasatinib and uses thereof
0
Edits on 23 Sep, 2022
"Entity importer update"
Golden AI
edited on 23 Sep, 2022
Infobox
Is a
Patent
0
Patent Jurisdiction
United States Patent and Trademark Office
0
Patent Number
10821375
0
Date of Patent
November 3, 2020
0
Patent Application Number
15562823
0
Date Filed
March 30, 2016
0
Official Website
https://pdfpiw.uspto.gov/.piw?Docid=10821375
0
Patent Citations Received
US Patent 11298356 Amorphous solid dispersions of dasatinib and uses thereof
0
US Patent 11324745 Amorphous solid dispersions of dasatinib and uses thereof
0
US Patent 11389450 Amorphous nilotinib microparticles and uses thereof
0
US Patent 11413290 Amorphous solid dispersions of dasatinib and uses thereof
0
Patent Primary Examiner
Andrew S Rosenthal
0
Edits on 17 Aug, 2022
"update inverses"
Golden AI
edited on 17 Aug, 2022
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent Citations Received
US Patent 11413290 Amorphous solid dispersions of dasatinib and uses thereof
Edits on 20 Jul, 2022
"update inverses"
Golden AI
edited on 20 Jul, 2022
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent citations received
US Patent 11389450 Amorphous nilotinib microparticles and uses thereof
Edits on 17 Jun, 2022
"Entity importer update"
Golden AI
edited on 17 Jun, 2022
Edits made to:
Infobox
(
+1
properties)
Infobox
Website URL
https://pdfpiw.uspto.gov/.piw?Docid=10821375
Edits on 19 May, 2022
"update inverses"
Golden AI
edited on 19 May, 2022
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent citations received
US Patent 11324745 Amorphous solid dispersions of dasatinib and uses thereof
Load more
Find more entities like US Patent 10821375 Continuous production of particles
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE